Editas Medicine will eliminate about 180 roles after failing to find a commercial partner for an experimental sickle cell ...

Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company ...

ICER reports $800M+ annual US cost increase from 5 drugs (Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz) with 2023 price ...

Former Padlock shareholders sue Bristol Myers Squibb over alleged unpaid milestone payments for antibody BMS-986454, claiming ...

Columvi combo in DLBCL, while AnaptysBio's ANB032 fails in atopic dermatitis. Essential Pharma gets €1.2B financing deal.

Daiichi Sankyo plans ADC facility in Shanghai, BioMarin expands in Cork, Vertex signs Saudi deal, EuroAPI CEO resigns, SK ...

Eli Lilly partners with telehealth company Ro to distribute discounted Zepbound vials at $399/month, while competitor Novo ...

Demis Hassabis has no interest in a laboratory. The Nobel Prize-winning artificial intelligence pioneer is betting big on ...

End­points News has once again reached out to a lengthy ros­ter of biotech ex­ecs to take their pulse on what’s ahead for the ...

Keros Therapeutics halts two dosing arms of cibotercept Phase 2 trial due to pericardial effusion safety concerns; continues ...

Illumina exec Vik Vaz as CEO to advance biological detection tech for drug research. The company uses what it calls ...

Corcept Therapeutics' dazucorilant fails Phase 2 ALS trial after missing primary endpoint, following October's Cushing's ...